REGN
Regeneron Pharmaceuticals Inc
Stock NASDAQ – Stock Market Prices, News & Analysis
Regeneron Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of treatments for serious diseases.
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of treatments for serious diseases.
Price history of Regeneron Pharmaceuticals Inc
Price history of Regeneron Pharmaceuticals Inc
Performance & Momentum
Regeneron Expands Dupixent, Enters Radiopharma
Regeneron is benefiting from new strategic milestones, with the European expansion of Dupixent in chronic spontaneous urticaria in children, in partnership with Sanofi. The approval further broadens the blockbuster drug’s commercial potential in a market where medical demand remains strong. The group also announced a collaboration with Telix Pharmaceuticals to develop and market next-generation radiopharmaceutical therapies for solid tumors. This move into an innovative segment strengthens medium-term growth prospects and is seen as mildly positive for the stock.
Strategic Analysis
Regeneron Pharmaceuticals Inc • 2026
Regeneron is an American biopharmaceutical company focused on innovation, with a model built on proprietary research and the monetization of high-value therapeutic franchises. The company stands out for its ability to extend the life of its flagship products while continuously refreshing its pipeline, enabling it to combine scientific expertise with growth drivers. Recent announcements around the expansion of Dupixent and its move into radiopharma confirm a strategy of broadening the portfolio and exploring new niche markets with strong potential.
- Recognized research platform, capable of generating differentiated drugs in complex therapeutic areas
- Strong commercial franchises and visible growth drivers around existing products
- Ability to position itself in new innovative segments, such as radiopharma, without losing its specialty pharma identity
- Significant dependence on pipeline success and the longevity of key products
- Valuation profile sensitive to clinical and regulatory signals, with medium-term visibility that can sometimes be uneven
Momentum has turned constructive again, with a clearly favorable trend reflecting renewed market confidence in the company’s trajectory. Recent performance suggests a more supportive dynamic than in recent years, even if the track record points to execution that has at times been uneven. Recent announcements regarding the expansion of Dupixent and the move into radiopharma strengthen the strategic narrative by showing that Regeneron can both defend its existing growth engines and open up new drivers of growth, which supports the stock’s medium-term appeal.
Similar stocks to Regeneron Pharmaceuticals Inc
Recent News
Regeneron Pharmaceuticals Inc
Regeneron's Dupixent Approved in Japan, Outlook Steady
3 months agoRegeneron Pharmaceuticals strengthens its position with Dupixent approval for children aged 6 to 11 with bronchial asthma in Japan, backed by phase 3 trials showing significant reduction in exacerbations and improved lung function. Morgan Stanley maintains a neutral rating while slightly raising its price target, citing reduced regulatory risks. The stock benefits from solid five-year growth, reflecting strong market confidence in its key franchises.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
